GRAS Screen™ 3 and GRAS Screen™ 4 were developed by Hampton Research for the crystallization of proteins, including monoclonal antibodies.
Each of the chemicals in GRAS Screen 3 and 4 have been used under one or more of the following categories. As (1) a Generally Recognized As Safe (GRAS) substance, (2) a pharmaceutical excipient, (3) a normal physiological constituent, (4) a metabolic byproduct, and/or (5) a Everything Added to Food in the United States (EAFUS) substance.
Formulation is based on a) data mining databases such as the Protein Data Bank (PDB), BMCD, and in house Hampton Research data, b) review and analysis of the patent and scientific literature, c) input from academic and pharma colleagues, and d) in house testing.
The primary crystallization reagent in GRAS Screen 3 and 4 are 24 unique salts (high concentration), versus Polyethylene glycol 300, 400, MME 550, 600, 1,000, MME 2,000, 3,350 and 4,000 as secondary reagents (low concentration), sampling pH 4 to 9 without an added buffer.
GRAS Screen 3 samples twenty four salts, encompassing pH 4-9 versus four low molecular weight Polyethylene glycols (300, 400, MME 550, & 600). GRAS Screen 3 is supplied in a 96 Deep Well block format and is compatible with robotic and multi-channel pipet liquid handling systems. GRAS Screen 3 is compatible with vapor diffusion, free interface diffusion, and microbatch crystallization methods. For research use only.
GRAS Screen 4 samples twenty four salts, encompassing pH 4-9 versus four medium molecular weight Polyethylene glycols (1,000, MME 2,000, 3,350 & 4,000). GRAS Screen 4 is supplied in a 96 Deep Well block format and is compatible with robotic and multi-channel pipet liquid handling systems. GRAS Screen 4 is compatible with vapor diffusion, free interface diffusion, and microbatch crystallization methods. For research use only.
1. Optimization of crystallization conditions for biological macromolecules. Alexander McPherson and Bob Cudney. Acta Crystallographica Section F Volume 70, Issue 11, pages 1445-1467, November 2014.
2. Crystallization of intact monoclonal antibodies. Harris LJ, Skaletsky E, McPherson A. Proteins. 1995 Oct;23(2):285-9.
3. Crystalline monoclonal antibodies for subcutaneous delivery. Yang MX1, Shenoy B, Disttler M, Patel R, McGrath M, Pechenov S, Margolin AL. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6934-9.
4. Fast and Scalable Purification of a Therapeutic Full-Length Antibody Based on Process Crystallization. Dariusch Hekmat et al, Biotechnology and Bioengineering, Vol. 110, No. 9, September, 2013.
5. Towards Protein Crystallization as a Process Step in Downstream Processing of Therapeutic Antibodies: Screening and Optimization at Microbatch Scale. Yuguo Zang et al, PLoS One. 2011; 6(9): e25282.
6. Crystallization as a tool for bioseparation. Bob Cudney, Am Biotechnol Lab. 1994 Jun;12(7):42.
7. Large-scale crystallization of proteins for purification and formulation. Hekmat D. Bioprocess Biosyst Eng. 2015 Jul;38(7):1209-31. doi: 10.1007/s00449-015-1374-y
8. Using X-Ray Crystallography to Simplify and Accelerate Biologics Drug Development. Brader ML, Baker EN, Dunn MF, Laue TM, Carpenter JF. J Pharm Sci. 2017 Feb;106(2):477-494. doi: 10.1016/j.xphs.2016.10.017.
9. Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions. Sandeep Nema and Ronald J. Brendell, PDA J Pharm Sci and Tech 2011, 65 287-332.